Bristol-Myers Squibb Co. and Lonza have entered a multi-year expansion of their existing biologics manufacturing agreement to include the production of commercial quantities of a second BMS biologic at Lonza’s mammalian manufacturing facility in Portsmouth, NH. Financial terms were not disclosed.   The companies have been collaborating since 2003 to produce commercial supplies of BMS biologics worldwide. Lonza also currently produces clinical supplies of an investigational biologic for BMS.   “O...